Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 8Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Zollinger-Ellison Syndrome 1Stomach Ulcer 1Solid Tumours 1Solid Tumor 1Prostate Cancer Patients 1Pharmacokinetics of MDV3100 1Ovarian Neoplasms 1Mouth Neoplasms 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Inflammation 1Hyperuricemia 1Healthy Adult Participants 1Gout 1Esophagitis, Peptic 1Colorectal Neoplasms 1Cardiovascular Diseases 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Arthritis 1Advanced Solid Tumours 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Carboplatin 367Pemetrexed 308pembrolizumab 302Cisplatin 242Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 78atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × Omeprazole × Clear all
NCT03531762 2023-07-28

Effect of a Proton Pump Inhibitor on the PK of Tepotinib

Merck KGaA, Darmstadt, Germany

Phase 1 Completed
12 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡